Medicine guide
Trevaclyn
·
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Laropiprant;nicotinic acid
- Made by
- Merck Sharp Dohme Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (LDL) cholesterol and triglycerides and low high-density-lipoprotein (HDL) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial). Trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-A (HMG-CoA)-reductase inhibitors (statins), when the cholesterol-lowering effect of HMG-CoA-reductase-inhibitor monotherapy is inadequate. It can be used as monotherapy only in patients in whom HMG-CoA-reductase inhibitors are considered inappropriate or not tolerated. Diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with Trevaclyn.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Merck Sharp Dohme Ltd |
|---|---|
| Active substance | Laropiprant;nicotinic acid |
| Used in | Heart, blood pressure and circulation |
| Classification | C10AD52 · Heart, blood pressure and circulation |
| Authorised on | 2008-07-03 |
| Last updated by the regulator | 2013-05-16 |
| EMA product number | EMEA/H/C/000897 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.